Companies › Beijing Continent Pharmaceutical
4 active drug programs in 6 registered trials: 2 Phase 1, 2 Phase 3, 2 Phase 2; Gastroenterology, Cardiovascular, Genitourinary, Respiratory; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Hydronidone capsules Pyridinone-based small molecule compound | – | Phase 3 | Liver Fibrosis; Renal Insufficiency Chronic | Dec 2026 |
| Pirfenidone Capsules | – | Phase 3 | Pneumoconiosis; Radiation-induced Lung Injury | Dec 2026 |
| F573 for injection | – | Phase 2 | Acute Liver Failure | – |
| F230 tablets Endothelin antagonist | – | Phase 1 | Pulmonary Hypertension | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06899815 | F230 tablets | Phase 1 | Pulmonary Hypertension | Cardiovascular | Jul 2026 |
| NCT05689645 | F573 for injection | Phase 2 | Acute Liver Failure | Gastroenterology | Sep 2026 |
| NCT05288179 | Pirfenidone Capsules | Phase 3 | Pneumoconiosis | Respiratory | Sep 2026 |
| NCT07262333 | Hydronidone capsules | Phase 1 | Renal Insufficiency Chronic | Genitourinary | Dec 2026 |
| NCT07388680 | Pirfenidone Capsules | Phase 2 | Radiation-induced Lung Injury | Respiratory | Dec 2026 |
| NCT05905172 | Hydronidone capsules | Phase 3 | Liver Fibrosis | Gastroenterology | Jun 2028 |
No annotated target.
–
Livzon Pharmaceutical Group Noorik Biopharmaceuticals Taisho Pharmaceutical Shin Poong Pharmaceutical Biocodex
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.